Foxo SPAC Presentation Deck

Comparable company analysis FOXO's focus on longevity differentiates it from peers '22E - ¹23E Revenue Growth '23E '24E Revenue Growth Average 2023E EV / Revenue Average 2024E EV / Revenue Fast Growing Recurring Revenues No / Limited Balance Sheet High R&D Expenditures Exclusive IP Regulatory Oversight FOXO(¹) FOXO FOXO INVESTOR DECK 2022 Page 38 156% 105% 2.5x 1.0x High Growth Distribution (2) BRP goosehead INSURANCE HAGERTY. RSG 36% 29% 8.2x 6.3x Diagnostics Biotech Adaptive BIOCARTIS EXACT SCIENCES Myriad genetics sema4 GUARDANT veracyte natera Prenetics 27% 28% 4.4X CareDx 3.6x INVITAE 23andMe (2) High Growth Distribution based on 2022E-2023E metrics due to lack of sufficient analyst estimates beyond 2023. (3) HSCM Public InsurTech Index comprised of BHG, BRP, CCCS, CLOV, DOMA, DCT, ESNT, EVER, GOCO, GSHD, GWRE, HIPO, KNSL, LMND, MAX, MILE, OSCR, PLMR, QNST, ROOT, SLQT, and TRUP. Insurtech (3³) HSCM Public InsurTech Index 29% 22% 3.0x Source: Company filings, investor presentations, FactSet, and SNL Market data as of 02/18/2022. Note: This slide contains projected financial information. Such projected financial information constitutes forward looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. (1) FOXO revenue growth rates based on '23E-'24E and '24E-25E to illustrate growth incorporating MGA business. 1.7x

View entire presentation